Research programme: idiopathic pulmonary fibrosis therapeutics - Endogena Therapeutics
Latest Information Update: 05 May 2021
At a glance
- Originator Endogena Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis
Most Recent Events
- 27 Apr 2021 Idiopathic pulmonary fibrosis therapeutics is available for licensing in World as of 27 Apr 2021. http://endogena.com/index.html
- 27 Apr 2021 Early research in Idiopathic pulmonary fibrosis in USA (unspecified route) (Endogena Therapeutics pipeline, April 2021)